Literature DB >> 10499626

Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas.

M Takahama1, M Tsutsumi, T Tsujiuchi, K Nezu, K Kushibe, S Taniguchi, Y Kotake, Y Konishi.   

Abstract

Expression of angiogenesis-associated genes was compared in 32 primary non-small cell lung carcinoma samples (14 adenocarcinomas, 17 squamous cell carcinomas, and 1 large cell carcinoma) and paired adjacent noncancerous lung tissues using a multiprobe RNase protection assay. Levels of Tie2, angiopoietin (Ang)-1, vascular endothelial growth factor (VEGF), and CD31 mRNAs were higher in cancers than in adjacent noncancerous tissues, in contrast to the fms-like tyrosine kinase (Flt)-1, Flt-4, Tie1, thrombin receptor, endoglin, and VEGF-C, for which no differences were evident. Overexpression did not seem to differ with histological type and pathological stage. Significant positive correlations were found between mRNA expression of Ang-1 and those of Tie2 and CD31, and that of VEGF and those of Flt-1 and CD31. These findings suggest that Ang-1 and VEGF are important angiogenic factors in human non-small cell lung carcinomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499626

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment.

Authors:  Melissa K Brunckhorst; Yin Xu; Rong Lu; Qin Yu
Journal:  Am J Pathol       Date:  2014-08       Impact factor: 4.307

2.  Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.

Authors:  Katsuhiro Masago; Daichi Fujimoto; Shiro Fujita; Akito Hata; Reiko Kaji; Kyoko Ohtsuka; Chiyuki Okuda; Jumpei Takeshita; Nobuyuki Katakami
Journal:  Mol Clin Oncol       Date:  2014-11-19

3.  Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors.

Authors:  Takayuki Nakayama; Lei Yao; Giovanna Tosato
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy.

Authors:  Kelly E Fathers; Courtney M Stone; Kanwal Minhas; Jason J A Marriott; Janice D Greenwood; Daniel J Dumont; Brenda L Coomber
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

5.  Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma.

Authors:  L Chen; Z Yang; G Wang; C Wang
Journal:  J Tongji Med Univ       Date:  2001

6.  Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis.

Authors:  Luni Emdad; Seok-Geun Lee; Zhao Zhong Su; Hyun Yong Jeon; Habib Boukerche; Devanand Sarkar; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-25       Impact factor: 11.205

7.  Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype.

Authors:  Dan Liu; Vanesa Martin; Juan Fueyo; Ok-Hee Lee; Jing Xu; Nahir Cortes-Santiago; Marta M Alonso; Kenneth Aldape; Howard Colman; Candelaria Gomez-Manzano
Journal:  Oncotarget       Date:  2010-12

8.  A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.

Authors:  Gargi D Basu; Winnie S Liang; Dietrich A Stephan; Lee T Wegener; Christopher R Conley; Barbara A Pockaj; Pinku Mukherjee
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

Review 9.  Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells.

Authors:  M J Hendrix; E A Seftor; D A Kirschmann; R E Seftor
Journal:  Breast Cancer Res       Date:  2000-08-11       Impact factor: 6.466

10.  Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1.

Authors:  S Tian; A J Hayes; L J Metheny-Barlow; L-Y Li
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.